OPKO to Sell BioReference Lab Testing Business to Labcorp for $722M Cash
OPK sits 64% above its 52-week low of $0.977 on elevated volume (14× avg).
Summary
OPKO agreed to sell BioReference's clinical and anatomic pathology lab testing business to Labcorp for $722M cash plus up to $150M in contingent 4Kscore payments. The deal is subject to HSR clearance and is expected to close by April 2027.
Key Events · M&A and Partnerships · OPK
-
Labcorp to Acquire BioReference Lab Business for $722M
OPKO's subsidiary BioReference Health agreed to sell its clinical and anatomic pathology laboratory testing business, including the 4Kscore prostate cancer test, to Laboratory Corporation of America Holdings for $722M in cash at closing.
-
Up to $150M in Contingent 4Kscore Payments
Labcorp will pay OPKO 15% of 4Kscore test cash receipts above a threshold, capped at $150M over up to 10 years, providing ongoing economics from the test's revenue.
-
HSR Clearance and Closing Conditions
The deal requires Hart-Scott-Rodino antitrust clearance and customary closing conditions, with an outside date of April 14, 2027. If HSR clearance fails, Labcorp pays OPKO a $28.88M termination fee.
-
Revenue-Based Purchase Price Adjustments
The $722M purchase price is subject to upward or downward adjustments based on Business revenues at closing, with a dispute resolution mechanism involving an independent CPA firm.
Analysis · OPK · Life Sciences
OPKO is divesting the bulk of BioReference's clinical and anatomic pathology lab testing business to Labcorp for $722M in cash at closing, plus up to $150M in contingent payments tied to the 4Kscore prostate cancer test over up to 10 years. For a company with a ~$1.2B market cap, this is a transformational transaction: the cash proceeds are substantial relative to OPKO's size and could fund debt reduction, its pharmaceutical pipeline, or other strategic priorities. The deal is subject to HSR antitrust clearance and customary closing conditions, with an outside date of April 14, 2027. If HSR clearance fails, Labcorp pays OPKO a $28.88M termination fee. The purchase price is also subject to revenue-based adjustments at closing. This marks a major strategic pivot, shrinking OPKO's diagnostics footprint while retaining the 4Kscore test economics through the contingent payment structure.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 45.4% of the 295 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OPK was trading at $1.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $0.98 to $1.75. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.